-
公开(公告)号:US06593335B1
公开(公告)日:2003-07-15
申请号:US09338889
申请日:1999-06-23
申请人: William A. Carroll , Yiyuan Chen , Mark W. Holladay , Michael E. Kort , Philip R. Kym , James P. Sullivan , Rui Tang , Lin Yi , Henry Q. Zhang , Irene Drizin
发明人: William A. Carroll , Yiyuan Chen , Mark W. Holladay , Michael E. Kort , Philip R. Kym , James P. Sullivan , Rui Tang , Lin Yi , Henry Q. Zhang , Irene Drizin
IPC分类号: A61K314365
CPC分类号: C07D221/04 , C07C45/00 , C07C45/298 , C07C45/41 , C07C45/63 , C07C45/71 , C07C205/44 , C07D215/36 , C07D495/04 , C07D495/14 , C07C47/565 , C07C47/55 , C07C49/753
摘要: Compounds having the formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
摘要翻译: 具有式I的化合物可用于治疗由钾通道开放剂预防或改善的疾病。 还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
-
公开(公告)号:US06645968B2
公开(公告)日:2003-11-11
申请号:US09777217
申请日:2001-02-05
申请人: Robert J. Altenbach , Hao Bai , Jorge D. Brioni , William A. Carroll , Murali Gopalakrishnan , Robert J. Gregg , Mark W. Holladay , Peggy P. Huang , John F. Kincaid , Michael E. Kort , Philip R. Kym , John K. Lynch , Arturo Perez-Medrano , Henry Q. Zhang
发明人: Robert J. Altenbach , Hao Bai , Jorge D. Brioni , William A. Carroll , Murali Gopalakrishnan , Robert J. Gregg , Mark W. Holladay , Peggy P. Huang , John F. Kincaid , Michael E. Kort , Philip R. Kym , John K. Lynch , Arturo Perez-Medrano , Henry Q. Zhang
IPC分类号: A61K314406
CPC分类号: C07D213/40 , A61K31/17 , A61K31/275 , A61K31/4406 , C07C233/78 , C07C233/83 , C07C271/22 , C07C275/28 , C07C275/30 , C07C279/28 , C07C279/36 , C07C335/16 , C07C335/18 , C07D209/08 , C07D213/74 , C07D213/75 , C07D213/82 , C07D215/38 , C07D233/42 , C07D233/84 , C07D235/06 , C07D239/42 , C07D333/20 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12
摘要: Compounds of formula I: are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
摘要翻译: 式I化合物可用于治疗用钾通道开放剂预防或改善的疾病。 还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
-
公开(公告)号:US06265417B1
公开(公告)日:2001-07-24
申请号:US09206055
申请日:1998-12-04
IPC分类号: A61K3147
CPC分类号: C07D221/04 , C07C45/298 , C07D215/36 , C07D495/04 , C07D495/14 , C07C47/55
摘要: Compounds having the formula are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
摘要翻译: 具有该化学式的化合物可用于治疗由钾通道开放剂预防或改善的疾病。 还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
-
公开(公告)号:US06274587B1
公开(公告)日:2001-08-14
申请号:US09443212
申请日:1999-11-19
申请人: Mark W. Holladay , William A. Carroll , Irene Drizin , Lin Yi , Henry Q. Zhang
发明人: Mark W. Holladay , William A. Carroll , Irene Drizin , Lin Yi , Henry Q. Zhang
IPC分类号: C07D23970
CPC分类号: C07D487/04 , C07D491/14 , C07D495/14
摘要: Compounds of formula I are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
摘要翻译: 式I化合物可用于治疗用钾通道开放剂预防或改善的疾病。 还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
-
公开(公告)号:US06538000B1
公开(公告)日:2003-03-25
申请号:US09709923
申请日:2000-11-10
申请人: Mark W. Holladay , William A. Carroll , Irene Drizin , Lin Yi , Henry Q. Zhang
发明人: Mark W. Holladay , William A. Carroll , Irene Drizin , Lin Yi , Henry Q. Zhang
IPC分类号: C07D47114
CPC分类号: C07D487/04 , C07D491/14 , C07D495/14
摘要: Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
摘要翻译: 式(I)化合物可用于治疗用钾通道开放剂预防或改善的疾病。 还公开了钾通道开放组合物和在哺乳动物中开放钾通道的方法。
-
公开(公告)号:US06403575B1
公开(公告)日:2002-06-11
申请号:US09619229
申请日:2000-07-19
申请人: Mark W. Holladay , Stephen P. Arneric , Hao Bai , Michael J. Dart , Nan-Horng Lin , John K. Lynch , Yat Sun Or , Keith B. Ryther , James P. Sullivan , James T. Wasicak , Paul P. Ehrlich
发明人: Mark W. Holladay , Stephen P. Arneric , Hao Bai , Michael J. Dart , Nan-Horng Lin , John K. Lynch , Yat Sun Or , Keith B. Ryther , James P. Sullivan , James T. Wasicak , Paul P. Ehrlich
IPC分类号: A61K3144
CPC分类号: A61K31/485 , A61K31/4427 , C07D205/04 , C07D401/12 , A61K2300/00
摘要: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
摘要翻译: 本发明涉及一种控制包括人在内的哺乳动物疼痛的方法,包括向需要治疗的哺乳动物或患者施用选择的式I化合物或其药学上可接受的盐。 本发明还涉及上述式(I)的选择的(R)和(S)化合物,其可用作止痛剂以及神经元细胞死亡预防剂和抗炎剂。
-
公开(公告)号:US6133253A
公开(公告)日:2000-10-17
申请号:US987581
申请日:1997-12-09
申请人: Mark W. Holladay , Stephen P. Arneric , Hao Bai , Michael J. Dart , Nan-Horng Lin , John K. Lynch , Yat Sun Or , Keith B. Ryther , James P. Sullivan , James T. Wasicak , Paul P. Ehrlich
发明人: Mark W. Holladay , Stephen P. Arneric , Hao Bai , Michael J. Dart , Nan-Horng Lin , John K. Lynch , Yat Sun Or , Keith B. Ryther , James P. Sullivan , James T. Wasicak , Paul P. Ehrlich
IPC分类号: A61K31/4427 , A61K31/485 , C07D205/04 , C07D401/12 , A61K31/44
CPC分类号: A61K31/485 , A61K31/4427 , C07D205/04 , C07D401/12
摘要: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: ##STR1## or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
摘要翻译: 本发明涉及一种控制包括人在内的哺乳动物疼痛的方法,包括向需要治疗的哺乳动物或患者施用选择的式I化合物或其药学上可接受的盐。 本发明还涉及上述式(I)的选择的(R)和(S)化合物,其可用作止痛剂以及神经元细胞死亡预防剂和抗炎剂。
-
公开(公告)号:US06503935B1
公开(公告)日:2003-01-07
申请号:US09364901
申请日:1999-07-29
申请人: Robert J. Altenbach , Michael D. Meyer , James F. Kerwin, Jr. , Mark W. Holladay , Albert Khilevich , Teodozyj Kolasa , Jeffrey Rohde , William A. Carroll
发明人: Robert J. Altenbach , Michael D. Meyer , James F. Kerwin, Jr. , Mark W. Holladay , Albert Khilevich , Teodozyj Kolasa , Jeffrey Rohde , William A. Carroll
IPC分类号: A61K31425
CPC分类号: C07D233/64 , C07D233/84 , C07D401/12 , C07D403/12 , C07D405/04 , C07D409/12 , C07D417/12
摘要: Compounds having formula I: are useful in treating diseases prevented by or ameliorated with &agr;1A agonists. Also disclosed are &agr;1A agonist compositions and a method of activating &agr;1 adrenoceptors in a mammal.
摘要翻译: 具有式I的化合物可用于治疗由α1A激动剂预防或改善的疾病。 还公开了α1A激动剂组合物和在哺乳动物中激活α1肾上腺素受体的方法。
-
公开(公告)号:US08633207B2
公开(公告)日:2014-01-21
申请号:US13222937
申请日:2011-08-31
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号: C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
摘要翻译: 本文提供了用于治疗JAK激酶介导的疾病的喹唑啉化合物,包括JAK2激酶,JAK3激酶或TYK2激酶介导的疾病。 还提供了包含该化合物的药物组合物和使用该化合物和组合物的方法。
-
公开(公告)号:US08618289B2
公开(公告)日:2013-12-31
申请号:US12933402
申请日:2009-03-17
申请人: Sunny Abraham , Shripad S. Bhagwat , Brian T. Campbell , Qi Chao , Raffaella Faraoni , Mark W. Holladay , Andiliy G. Lai , Martin W. Rowbottom , Eduardo Setti , Kelly G. Sprankle
发明人: Sunny Abraham , Shripad S. Bhagwat , Brian T. Campbell , Qi Chao , Raffaella Faraoni , Mark W. Holladay , Andiliy G. Lai , Martin W. Rowbottom , Eduardo Setti , Kelly G. Sprankle
IPC分类号: C07D239/70 , A01N43/54
CPC分类号: C07D239/88 , A61K9/20 , A61K9/48 , A61K31/517 , A61K45/06 , C07D239/93 , C07D261/14 , C07D413/12
摘要: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
摘要翻译: 提供根据式(I)的化合物,组合物和方法用于调节RAF激酶(包括BRAF激酶)的活性,并用于治疗,预防或改善由RAF激酶介导的疾病或病症的一种或多种症状。 式(I):或其药学上可接受的盐,溶剂合物,其水合物的包合物,其中X为O或S(O)t; Ra是O或S.
-
-
-
-
-
-
-
-
-